drugset / Trial / NCT06395441

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

NCT06395441

Phase 3 Recruiting 160 enrolled Mayo Clinic
RandomizedParallel-groupDouble-blindSupportive care

Summary

This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fatigue is among the most challenging symptoms to manage in patients with cancer, both on or off active treatment. This symptom complex meaningfully contributes to psychosocial distress, healthcare costs, and it also interferes with the delivery of anticancer therapies. American ginseng (Western ginseng) appears to be a promising appearing agent for treating cancer related fatigue. Western ginseng may reduce cancer-related fatigue.

Timeline

Start
2024-08-01
Primary completion
2026-11-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject American ginseng Unknown Oral

Indications